TGFB1 and systemic sclerosis: Although no studies have directly investigated the application of TGF-β1-targeting drugs in CMBS, the bronchial wall fibrosis observed in CMBS shares high similarity in its core pathological mechanisms with other fibrotic diseases driven by TGF-β1, such as pulmonary fibrosis and systemic sclerosis.